| Hans-Günter Meyer-Thompson | Hepatitiden
A decade of HCV drugs
A decade of HCV drugs
The FDA’s approval of Gilead’s hepatitis C virus (HCV) drug sofosbuvir (Sovaldi) in December 2013 made big healthcare waves. Drug developers heralded the long-awaited arrival of a wonder drug that promised to wipe out a previously hard-to-treat virus. Patients looked forward to relief from a chronic infection, if they could get the drug. And Medicare and insurance companies worried that the pricey new antiviral would break the bank. (Nature News, 06.12.2023)